Literature DB >> 12324805

Antiemetic guidelines: creating a more practical treatment approach.

Jim M Koeller1, Matti S Aapro, Richard J Gralla, Steven M Grunberg, Paul J Hesketh, Mark G Kris, Rebecca A Clark-Snow.   

Abstract

Antiemetic guidelines from a variety of professional organizations have been available for several years. It is unclear just how often these guidelines have been used, however; data indicate that some practitioners still do not treat their patients according to the recommendations. Some of those involved in the creation of the original guidelines convened to try to create a simpler, more practical approach to the use of antiemetics in preventing chemotherapy-induced nausea and vomiting. The group's intention was to clarify available guidelines and produce a practical document, based on evidence, that could be used in everyday practice. The group created four consensus statements that would serve as a basis for their recommendations. One primary strategy used was to have chemotherapy-induced nausea and vomiting viewed as a single process that can occur throughout a treatment cycle, and not so much as an acute and a delayed process, as is usual in clinical trials. Patients' management should be considered over a 4- to 5-day period, rather than primarily dealing with the day of treatment only. The group created three tables: emetic risk of chemotherapy; treatment options based on emetic category; and antiemetic dosing recommendations. Use of these tables should make appropriate antiemetic selection more straightforward and easier for the practitioner in an everyday setting. Although this document alone may not solve all the challenges with appropriate antiemetic management, it will hopefully prove to be a step in the right direction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12324805     DOI: 10.1007/s00520-001-0335-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  20 in total

1.  The importance of clinical practice guidelines (CPGs) for the quality and development of supportive care in Central and Eastern European (CEE) countries.

Authors:  Snezana Bosnjak
Journal:  Support Care Cancer       Date:  2003-10-15       Impact factor: 3.603

2.  Ondansetron treatment in a child presenting with chronic intractable pruritus.

Authors:  Chantal Frigon; Joëlle Desparmet
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

3.  The cost of chemotherapy-induced nausea and vomiting in Italy.

Authors:  Enzo Ballatori; Fausto Roila; Benedetta Ruggeri; Stella Porrozzi; Mauro Iannopollo; Giancarla Soru; Giorgio Cruciani; Bruno Daniele; Maria Cristina Locatelli; James Pellissier; Robert Deuson
Journal:  Support Care Cancer       Date:  2006-06-21       Impact factor: 3.603

4.  Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis.

Authors:  Karin Jordan; Axel Hinke; Axel Grothey; Hans Joachim Schmoll
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

5.  Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.

Authors:  Ronald Chow; Crystal Valdez; Natalie Chow; Daniel Zhang; James Im; Emily Sodhi; Michael Lock
Journal:  Support Care Cancer       Date:  2020-01-08       Impact factor: 3.603

6.  Efficacy of palonosetron and ramosetron on postoperative nausea and vomiting related to intravenous patient-controlled analgesia with opioids after gynecological laparoscopic surgery (double-blinded prospective randomized controlled trial).

Authors:  Seong-Hyop Kim; Chung-Sik Oh; Sun Joo Lee
Journal:  J Anesth       Date:  2015-03-04       Impact factor: 2.078

7.  Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.

Authors:  Agnes Glaus; Cornelia Knipping; Rudolf Morant; Christel Böhme; Burkhard Lebert; Frank Beldermann; Bernhard Glawogger; Paz Fernandez Ortega; André Hüsler; Robert Deuson
Journal:  Support Care Cancer       Date:  2004-10       Impact factor: 3.603

8.  Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial.

Authors:  Mamoru Tsukuda; Junichi Ishitoya; Yasukazu Mikami; Hideki Matsuda; Hideaki Katori; Choichi Horiuchi; Machiko Kimura; Takahide Taguchi; Takafumi Yoshida; Junichi Nagao; Yasunori Sakuma; Gabor Toth
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

9.  Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.

Authors:  Young Mi Seol; Hyo Jeong Kim; Young Jin Choi; Eun Mi Lee; Yang Soo Kim; Sung Yong Oh; Su Jin Koh; Jin Ho Baek; Won Sik Lee; Young Don Joo; Hyun Gi Lee; Eun Young Yun; Joo Seop Chung
Journal:  Support Care Cancer       Date:  2015-08-12       Impact factor: 3.603

Review 10.  Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.

Authors:  Rudolph M Navari
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.